Kathmandu— US President Donald Trump has directed an end to federal funding for “gender-affirming care” for minors through Medicaid and the Children’s Health Insurance Program (CHIP), marking a significant shift in policy regarding transgender healthcare access. The decision follows a review that raised concerns about the long-term effects of treatments like puberty blockers, hormones, and surgeries on young people. These restrictions are set to take effect October 13th, impacting low-income families who rely on these programs for their children’s healthcare needs, while states retain the option to fund such care independently.

Policy Rollback and Rationale

The Trump administration framed the decision as a protective measure for children, arguing against what they describe as “barbaric surgeries and practices.” In a post on Truth Social, President Trump stated his opposition to federal funds being used for procedures that could cause “irreversible harm” to young bodies. This action is part of a larger effort to reverse policies related to transgender rights implemented by previous administrations, encompassing areas like sports participation and military service.

CMS Findings and Medical Concerns

The Centers for Medicare and Medicaid Services (CMS) stated the decision was based on a Department of Health and Human Services review that identified gaps in evidence supporting medical gender transition for minors. CMS Administrator Mehmet Oz argued that ending federal funding would both save taxpayer money and protect children from potentially irreversible harm, citing risks such as infertility, impaired sexual function, and reduced bone density. The agency also highlighted evolving medical guidance, referencing concerns raised by organizations like the American Society of Plastic Surgeons and the UK’s Cass Review regarding limited evidence of benefit in minors.

State-Level Actions and Existing Restrictions

The federal restrictions build upon a growing trend of limitations on gender-transition treatment for minors at the state level. At least 27 US states have already enacted similar restrictions, while several major hospitals have paused or stopped offering certain procedures due to legal challenges, funding pressures, and shifting medical perspectives. Individual states are still able to utilize their own funds to provide coverage for these treatments if they choose.

Coverage Transition Details

The new rules will cover puberty blockers, cross-sex hormones, and surgical procedures. Children currently undergoing hormone therapy will be allowed a six-month tapering period before federal funding is discontinued. Importantly, the restrictions do not affect federal coverage for mental health services related to gender dysphoria.

The policy change is expected to face legal challenges and further intensify the debate surrounding transgender healthcare access in the United States. The full impact on affected families will become clearer as the October 13th implementation date approaches.

(With inputs from RT)

Originally published on abcnews.com.np.